Terry Jones worked as a welder and electrician for about twenty-eight years. He regularly used mild-steel welding rods made or distributed by the defendants. Welding fumes from those rods contained small amounts of manganese. Jones later developed Parkinsonian symptoms and claimed that chronic inhalation of manganese caused manganism, a neurological condition distinct from idiopathic Parkinson’s disease. He sued the manufacturers and distributors for negligence and strict products liability, chiefly alleging inadequate warnings.
The central trial dispute was medical causation. Jones’s expert diagnosed manganism based largely on Jones’s welding history and a finding of myoclonus. The defendants presented Jones’s treating neurologists and their own expert, all of whom concluded that Jones had idiopathic Parkinson’s disease rather than manganese-induced manganism. The jury found for the defendants on all counts.
After the district court denied Jones’s Rule 59 motion for a new trial, Jones appealed, challenging testimony by the defendants’ metallurgy expert, Dr. Thomas Eager, and defense counsel’s closing argument. While that appeal was pending, Jones sought relief under Rule 60(b)(2), claiming newly discovered evidence showed that Eager had testified falsely, and he moved to hold Eager in civil contempt. The district court denied both motions. The Seventh Circuit affirmed the judgment and all post-trial orders.
Issue #1
Whether the district court’s admission of Dr. Eager’s testimony about the joint animal-lung research required a new trial.
Holding
No. Dr. Eager likely lacked the Rule 702 qualifications to testify about medical and toxicological conclusions from the research, but the error was harmless.
Reasoning
Rule 702 permits expert testimony only when the opinion is grounded in the witness’s own knowledge, skill, experience, training, or education. Dr. Eager was qualified in metallurgy and materials science, but the disputed testimony concerned the body’s absorption of manganese and the toxicological effects of welding fumes on animal lungs—subjects medical and biological in nature.
Eager admitted that he was not a toxicologist and had no demonstrated expertise in assessing manganese’s health effects apart from his limited involvement with the research. His attendance at meetings and discussions with medical researchers did not establish the sustained, hands-on expertise necessary to offer their medical conclusions as his own. If he was simply relaying Dr. Brain’s conclusions, Dr. Brain was the appropriate witness to explain them.
Still, an evidentiary error warrants a new trial only if it affected a substantial right—meaning there was a significant chance it affected the verdict. The decisive question was whether Jones had manganism at all, not simply whether welding fumes could theoretically cause manganism.
The medical evidence strongly supported idiopathic Parkinson’s disease. Jones’s treating physicians and the defendants’ neurologist diagnosed idiopathic Parkinson’s disease; Jones showed features associated with that condition, including resting tremor, asymmetrical symptoms, and a favorable response to dopamine therapy. His expert’s contrary diagnosis was weakened because it depended substantially on work history and myoclonus that other physicians did not observe.
The jury also had reasons to discount Eager’s medical testimony. Jones cross-examined Eager about his lack of medical or toxicological expertise, and the defendants introduced no underlying research documents. Moreover, Jones offered studies and expert testimony supporting the proposition that welding-fume manganese could cause neurological injury. Excluding Eager’s testimony therefore probably would not have changed the result.
Issue #2
Whether Dr. Eager’s undisclosed testimony about the Caterpillar epidemiological study required a new trial under Rules 26 and 37.
Holding
No. Jones’s objection was timely, and the study should have been disclosed, but any error in allowing the testimony was harmless.
Reasoning
Jones objected at the close of Eager’s testimony rather than at the instant the study was mentioned. That objection was sufficiently contemporaneous under Evidence Rule 103 because the court still could have cured any error through a limiting instruction while the testimony remained fresh. A timely objection need not always be perfectly simultaneous with the challenged evidence.
Rule 26 required the defendants to disclose the opinions Eager would offer and the information he considered. Rule 37(c)(1) generally bars undisclosed information unless the nondisclosure was substantially justified or harmless. The defendants did not disclose that Eager would rely on the Caterpillar Study, and the district court had not addressed whether the omission was harmless because it deemed Jones’s objection waived.
Even assuming the nondisclosure was unjustified, the testimony was harmless. Eager’s statement about the study was a single question-and-answer exchange, the study itself was not admitted, and the statement was cumulative of his broader claim that welding-fume exposure was insufficient to cause disease.
For the same reasons that made the joint-research testimony harmless, this testimony was unlikely to affect the verdict. The core causation issue was whether Jones suffered manganism rather than idiopathic Parkinson’s disease, and the medical evidence heavily favored the latter diagnosis.
Issue #3
Whether defense counsel’s references to Jones’s effort to “trick” or distract the jury during closing argument required a new trial.
Holding
No. The argument did not constitute reversible misconduct and, in any event, did not substantially prejudice Jones.
Reasoning
Closing argument permits counsel to discuss weaknesses in the opposing party’s proof and to urge reasonable inferences from the record. In context, defense counsel’s remarks argued that Jones was diverting the jury from the central medical-causation problem: the extensive evidence that Jones had idiopathic Parkinson’s disease rather than manganism.
The court did not read the comments as an impermissible personal attack on Jones or his lawyers. Although the terms “trick” and “trick-pack” were pointed and could have had an inflammatory effect, they were brief and were connected to the defendants’ evidence-based argument that Jones had failed to establish manganese-induced disease.
Reversal for improper closing remarks requires statements that are plainly unwarranted and clearly injurious, causing substantial prejudice. The overwhelming medical evidence favored the defendants, and Jones did not show that the remarks changed the jury’s decision.
The district court also instructed the jury that lawyers’ statements and arguments were not evidence and that the verdict had to rest on admitted evidence. The appellate court presumed the jury followed that instruction, which further reduced any possible prejudice.
Issue #4
Whether Jones was entitled to Rule 60(b)(2) relief based on allegedly newly discovered evidence that Dr. Eager testified falsely.
Holding
No. Even assuming the evidence was new and Eager’s testimony was false, Jones did not show that a new trial would probably produce a different result.
Reasoning
Rule 60(b)(2) is an extraordinary remedy. A movant must show that the evidence was discovered after trial, could not have been found sooner with due diligence, is not merely cumulative or impeaching, is material, and would probably produce a different result at a new trial. Failure on any one element defeats the motion.
Jones asserted that later testimony and documents showed Eager overstated his role in the joint research, mischaracterized its conclusions, and misrepresented the Caterpillar Study. The district court found that some of this material was not truly new and that the remaining evidence did not establish a material falsehood, but the Seventh Circuit did not need to resolve each of those issues.
The dispositive defect was materiality and probable effect on the verdict. The challenged testimony was essentially the same testimony that the court had already deemed harmless in the direct appeal. Removing it from a retrial would not likely overcome the powerful medical evidence that Jones had idiopathic Parkinson’s disease rather than manganism.
Jones had also undermined Eager’s testimony at trial by establishing that Eager was not a medical or toxicological expert and by stressing that lung studies did not directly resolve Jones’s alleged brain injury. His own medical expert supplied contrary testimony on the effects of manganese. Thus, the district court reasonably concluded that a new trial would probably yield the same verdict.
Issue #5
Whether Dr. Eager could be held in civil contempt for allegedly giving false testimony at trial.
Holding
No. False testimony alone, without violation of a specific court order or an additional obstruction of the court’s authority, does not support civil contempt.
Reasoning
Civil contempt is a limited remedial and coercive power. It is used to compel compliance with a clear court order or to compensate a party for losses caused by disobedience of such an order. A contempt sanction must rest on an explicit, unequivocal judicial command that the alleged contemnor violated.
Eager took the ordinary witness oath to testify truthfully, but the oath was not a specific court order whose violation could support civil contempt. Nor could the requested sanctions coerce future compliance because the trial had already ended.
Supreme Court precedent distinguishes perjury from contempt. False testimony may undermine the truth-seeking goal of a trial, but trials are designed to resolve conflicting evidence, including potentially false evidence. Perjury becomes contempt only when an additional obstructive act impedes the court’s performance of its duties.
Jones alleged no obstruction beyond the asserted falsity itself. His proper potential remedies were a new-trial motion and, where appropriate, criminal prosecution for perjury—not civil contempt, damages, or disgorgement against the witness.